Intramural Research Program, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland 20892, United States.
Strait Laboratory of Flexible Electronics (SLoFE), Fujian Key Laboratory of Flexible Electronics, Strait Institute of Flexible Electronics (Future Technologies), Fujian Normal University, Fuzhou 350117, China.
J Am Chem Soc. 2024 Oct 23;146(42):28973-28984. doi: 10.1021/jacs.4c09831. Epub 2024 Oct 9.
Activation of the innate immune Stimulator of Interferon Genes (STING) pathway potentiates antitumor immunity. However, delivering STING agonists systemically to tumors presents a formidable challenge, and resistance to STING monotherapy has emerged in clinical trials with diminishing natural killer (NK) cell proliferation. Here, we encapsulated the STING agonist diABZI within polymersomes containing a Type I photosensitizer (NBS), creating a nanoagonist (PNBS/diABZI) for highly responsive tumor immunotherapy. This structure promoted H-aggregation and intersystem crossing of NBS, resulting in a ∼ 3-fold amplification in superoxide anion and singlet oxygen generation. The photodynamic therapy directly damaged hypoxia tumor cells and stimulated the proliferation of NK cells and cytotoxic T lymphocytes, thereby sensitizing STING immunotherapy. A single systemic intravenous administration of PNBS/diABZI eradicated orthotopic mammary tumors in murine models, achieving long-term antitumor immune memory to inhibit tumor recurrence and metastasis and significantly improving long-term tumor-free survival. This work provides a design rule for boosting reactive oxygen species production by promoting the intersystem crossing process, highlighting the potential of Type I photosensitizer-polymer vehicles for augmenting STING immunotherapy.
先天免疫干扰素基因刺激物 (STING) 通路的激活增强了抗肿瘤免疫。然而,全身性递送 STING 激动剂到肿瘤中存在巨大的挑战,并且在临床试验中已经出现了对 STING 单药治疗的耐药性,其表现为自然杀伤 (NK) 细胞增殖减少。在这里,我们将 STING 激动剂 diABZI 封装在含有 I 型光敏剂 (NBS) 的聚合物泡囊内,构建了一种用于高度响应性肿瘤免疫治疗的纳米激动剂 (PNBS/diABZI)。这种结构促进了 NBS 的 H-聚集和系间穿越,导致超氧阴离子和单线态氧的生成分别放大了约 3 倍。光动力疗法直接损伤缺氧肿瘤细胞,并刺激 NK 细胞和细胞毒性 T 淋巴细胞的增殖,从而敏化 STING 免疫治疗。单次系统静脉注射 PNBS/diABZI 即可根除原位乳腺肿瘤,在小鼠模型中实现了长期抗肿瘤免疫记忆,从而抑制肿瘤复发和转移,并显著提高长期无肿瘤生存。这项工作为通过促进系间穿越过程来提高活性氧的产生提供了一个设计规则,突出了 I 型光敏剂-聚合物载体在增强 STING 免疫治疗方面的潜力。